Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates through two segments, Services and True Health. The Services segment provides value-based care services that include Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows and engages patients; population health performance that delivers patient-centric cost effective care; and delivery network alignments. This segment also offers specialty care management solutions that support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation, and specific market dynamics; and comprehensive health plan administrative services that helps providers assemble the complete infrastructure required to operate, manage, and capitalize on a variety of financial and administrative management services. The True Health segment operates a commercial health plan for small and large businesses in New Mexico. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
IPO Year: 2015
Exchange: NYSE
Website: evolenthealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/8/2024 | $38.00 → $16.00 | Overweight → Equal-Weight | Stephens |
| 10/11/2024 | $35.00 | Overweight | KeyBanc Capital Markets |
| 8/9/2024 | $28.00 → $33.00 | Hold → Buy | Truist |
| 4/22/2024 | $40.00 | Buy | Citigroup |
| 3/1/2024 | $45.00 | Outperform | Oppenheimer |
| 1/3/2024 | $39.00 | Overweight | Barclays |
| 12/6/2023 | $37.00 | Mkt Outperform | JMP Securities |
| 10/16/2023 | $46.00 | Buy | UBS |
| 4/12/2023 | $40.00 | Overweight | Stephens |
| 11/1/2022 | $33.00 | Hold | Truist |
The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companie
WASHINGTON, Dec. 1, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent"), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Seth R. Frank has joined the company as Vice President, Investor Relations, effective immediately. Reporting to John Johnson, Evolent's Chief Financial Officer, Seth will lead Evolent's investor relations (IR) strategy and oversee its relationships with the investment community. "Seth provides a demonstrated track record of proactive, finance-driven leadership in health care investor relations to Evolent," said Evolent Health Chief Financial Officer John Johnson. "He brings long-ter
WASHINGTON, Jan. 13, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Kim A. Keck has been appointed to its Board of Directors, effective immediately and will stand for election at the Company's 2021 annual meeting of stockholders. Ms. Keck has more than 30 years' experience in the health care industry and currently serves as President and Chief Executive Officer of the Blue Cross Blue Shield Association (BCBSA), a national federation of 36 independent, community-based and locally operated Blue Cross and Blue Shield companies that provide health care coverag
Partnership Focuses on Improving Prior Authorization Process, Helping Drive Better Patient Outcomes Humana Inc. (NYSE:HUM) and Evolent Health, Inc. (NYSE:EVH) announced they have expanded their strategic medical oncology partnership to modernize and streamline prior authorization processes to include radiation and surgical oncology services. By connecting all primary approaches to treating cancer, this collaboration will help expedite approval of prior authorization requests, improve patient access to care, and ensure timely access to critical treatments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107578119/en/ "This part
Revenue of $621.4 million, an increase of $110.4 million or 21.6%, from the three months ended September 30, 2023.Net loss attributable to common shareholders of Evolent Health, Inc. of $(31.2) million and a net loss margin of (5.0)%.Adjusted EBITDA of $31.8 million resulting in an Adjusted EBITDA margin of 5.1%.Revises outlook for Adjusted EBITDA for 2024.Reiterates average annual long-term revenue and average Adjusted EBITDA growth rate targets.Announces record six new contract agreements in the quarter.WASHINGTON, Nov. 7, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions th
The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companie
Company to Participate in Upcoming Conferences WASHINGTON, Oct. 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9
Revenue of $647.1 million, an increase of $178.0 million or 37.9%, from the three months ended June 30, 2023.Net loss attributable to common shareholders of Evolent Health, Inc. of $(6.4) million and a net loss margin of (1.0)%.Adjusted EBITDA of $52.0 million resulting in an Adjusted EBITDA margin of 8.0%.Narrows revenue outlook for full year 2024 and provides updated 2024 Adjusted EBITDA guidance.Reiterates confidence in achieving $300 million in Adjusted EBITDA run rate exiting 2024.WASHINGTON, Aug. 8, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care
Company to Participate in Upcoming Conferences WASHINGTON, July 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations
Machinify solution seeks to accelerate the efficiency, quality, and clinical value of Evolent's specialty condition management platform through AI-enabled clinical workflow automationMachinify technology leverages the latest advances in applied machine learning, large language models and data analyticsAcquisition expected to benefit health plans, clinicians, and membersWASHINGTON, June 4, 2024 /PRNewswire/ -- Evolent Health, Inc. ("Evolent" or "the Company"), (NYSE:EVH) a company focused on achieving better health outcomes for people with complex conditions, today announced it has entered into an agreement to acquire certain assets of Machinify and the exclusive, perpetual and royalty-free l
Digital cancer care platform Careology and Evolent (NYSE:EVH) to offer an innovative platform to enable cancer navigationEvolent will embed Careology's digital cancer care technology within its comprehensive care navigation services offered to health plan clients across the U.S.WASHINGTON, May 9, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a $2 billion revenue company focused on achieving better health outcomes for people with complex conditions, today announced it is partnering with Careology, a digital cancer care platform, to enable more coordinated, connected and empowered journeys for people living with cancer in the U.S. Evolent works with more than 70 health plans — spanning
Revenue of $639.7 million, an increase of $212.0 million or 49.6%, from the three months ended March 31, 2023.Net loss attributable to common shareholders of Evolent Health, Inc. of $(25.2) million and a net loss margin of (3.9)%.Adjusted EBITDA of $54.1 million resulting in an Adjusted EBITDA margin of 8.5%.Raises revenue outlook for full year 2024 and reiterates full year 2024 Adjusted EBITDA guidance.WASHINGTON, May 9, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the quarter ended
Company to Participate in Upcoming Conferences WASHINGTON, April 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable, today announced it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolenthealth.com. Analysts interested in asking questions during the live call should dial 855.940.
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
Stephens downgraded Evolent Health from Overweight to Equal-Weight and set a new price target of $16.00 from $38.00 previously
KeyBanc Capital Markets initiated coverage of Evolent Health with a rating of Overweight and set a new price target of $35.00
Truist upgraded Evolent Health from Hold to Buy and set a new price target of $33.00 from $28.00 previously
Citigroup initiated coverage of Evolent Health with a rating of Buy and set a new price target of $40.00
Oppenheimer initiated coverage of Evolent Health with a rating of Outperform and set a new price target of $45.00
Barclays initiated coverage of Evolent Health with a rating of Overweight and set a new price target of $39.00
JMP Securities initiated coverage of Evolent Health with a rating of Mkt Outperform and set a new price target of $37.00
UBS initiated coverage of Evolent Health with a rating of Buy and set a new price target of $46.00
Stephens initiated coverage of Evolent Health with a rating of Overweight and set a new price target of $40.00
Truist initiated coverage of Evolent Health with a rating of Hold and set a new price target of $33.00
Revenue of $621.4 million, an increase of $110.4 million or 21.6%, from the three months ended September 30, 2023.Net loss attributable to common shareholders of Evolent Health, Inc. of $(31.2) million and a net loss margin of (5.0)%.Adjusted EBITDA of $31.8 million resulting in an Adjusted EBITDA margin of 5.1%.Revises outlook for Adjusted EBITDA for 2024.Reiterates average annual long-term revenue and average Adjusted EBITDA growth rate targets.Announces record six new contract agreements in the quarter.WASHINGTON, Nov. 7, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions th
Company to Participate in Upcoming Conferences WASHINGTON, Oct. 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9
Revenue of $647.1 million, an increase of $178.0 million or 37.9%, from the three months ended June 30, 2023.Net loss attributable to common shareholders of Evolent Health, Inc. of $(6.4) million and a net loss margin of (1.0)%.Adjusted EBITDA of $52.0 million resulting in an Adjusted EBITDA margin of 8.0%.Narrows revenue outlook for full year 2024 and provides updated 2024 Adjusted EBITDA guidance.Reiterates confidence in achieving $300 million in Adjusted EBITDA run rate exiting 2024.WASHINGTON, Aug. 8, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care
Company to Participate in Upcoming Conferences WASHINGTON, July 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations
Revenue of $639.7 million, an increase of $212.0 million or 49.6%, from the three months ended March 31, 2023.Net loss attributable to common shareholders of Evolent Health, Inc. of $(25.2) million and a net loss margin of (3.9)%.Adjusted EBITDA of $54.1 million resulting in an Adjusted EBITDA margin of 8.5%.Raises revenue outlook for full year 2024 and reiterates full year 2024 Adjusted EBITDA guidance.WASHINGTON, May 9, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the quarter ended
Company to Participate in Upcoming Conferences WASHINGTON, April 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable, today announced it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolenthealth.com. Analysts interested in asking questions during the live call should dial 855.940.
WASHINGTON, Feb. 22, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months and year ended December 31, 2023. Seth Blackley, Chief Executive Officer, and Co-Founder of Evolent stated, "We ended 2023 on a strong note, achieving all of our financial objectives for the year. Annual revenue increased over 45% while we continued to deliver strong earnings, driven by continued underlying growth as well as the successful integration of NIA. I am incredibly proud of our global team who
Company to Participate in Upcoming Investor Conferences WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its fourth quarter 2023 financial results on Thursday, Feb. 22, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolenthealth.com. Analysts interested in asking questions during the live call should
WASHINGTON, Oct. 10, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its third quarter 2023 financial results on Thursday, Nov. 2, 2023, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, ir.evolenthealth.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and r
WASHINGTON, Aug. 2, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the quarter ended June 30, 2023. Highlights from the second quarter 2023 announcement include: Revenue of $469.1 million, an increase of $149.2 million, or 46.6%, from the three months ended June 30, 2022.Net loss attributable to common shareholders of Evolent Health, Inc. of $41.4 million resulting in a net loss margin of (8.8)%.Adjusted EBITDA of $47.4 million resulting in an Adjusted EBITDA margin of 10.1%.Total Lives
8-K - Evolent Health, Inc. (0001628908) (Filer)
8-K - Evolent Health, Inc. (0001628908) (Filer)
8-K - Evolent Health, Inc. (0001628908) (Filer)
8-K - Evolent Health, Inc. (0001628908) (Filer)
8-K - Evolent Health, Inc. (0001628908) (Filer)
ARS - Evolent Health, Inc. (0001628908) (Filer)
DEFA14A - Evolent Health, Inc. (0001628908) (Filer)
DEF 14A - Evolent Health, Inc. (0001628908) (Filer)
S-3ASR - Evolent Health, Inc. (0001628908) (Filer)
8-K - Evolent Health, Inc. (0001628908) (Filer)
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume BSX PUT SWEEP BEARISH 08/16/24 $75.00 $68.9K 5.5K 2.1K MRNA CALL SWEEP NEUTRAL 11/15/24 $170.00 $121.
Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $44 to $41.
JMP Securities analyst Constantine Davides maintains Evolent Health (NYSE:EVH) with a Market Outperform and lowers the price target from $38 to $34.
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results. Diodes posted adjusted earnings of 28 cents per share, missing market estimates of 31 cents per share. The company's quarterly sales came in at $301.97 million missing expectations of $305.01 million, according to data from Benzinga Pro. Diodes shares dipped 9.8% to $68.99 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novavax, Inc. (NASDAQ:NVAX) shares jumped 139% to $10.73 after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and d
Digital cancer care platform Careology and Evolent (NYSE:EVH) to offer an innovative platform to enable cancer navigationEvolent will embed Careology's digital cancer care technology within its comprehensive care navigation services offered to health plan clients across the U.S.WASHINGTON, May 9, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a $2 billion revenue company focused on achieving better health outcomes for people with complex conditions, today announced it is partnering with Careology, a digital cancer care platform, to enable more coordinated, connected and empowered journeys for people living with cancer in the U.S.Evolent works with more than 70 health plans — spanning
Second Quarter 2024 GuidanceFor the three months ended June 30, 2024, revenue is expected to be in the range of approximately $625.0 million to $645.0 million. Adjusted EBITDA is expected to be in the range of approximately $48.0 million to $62.0 million.The Company noted that the wide range for its second quarter outlook for Adjusted EBITDA is driven by higher leading indicator volume in certain Performance Suite contracts in Q1, combined with lower claims visibility from partners in part due to the Change Healthcare cyber-attack. Together these variables resulted increased conservatism for Q2 guidance.Full Year 2024 Guidance For year ending December 31, 2024, revenue is expected to be in t
SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)
SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)
SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)
SC 13G - Evolent Health, Inc. (0001628908) (Subject)
SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)
SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)
SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)
SC 13G - Evolent Health, Inc. (0001628908) (Subject)
SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)
SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)